



(51) International Patent Classification:

C07D 491/08 (2006.01) *A61K 31/475* (2006.01)
A61K 31/4741 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2013/025247

(22) International Filing Date:

8 February 2013 (08.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/598,143 13 February 2012 (13.02.2012) US
 61/653,785 31 May 2012 (31.05.2012) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
 [US/US]; Route 206 and Province Line Road, Princeton,
 New Jersey 08543-4000 (US).

(72) Inventors: **CHOWDARI, Naidu S.**; c/o Bristol-Myers
 Squibb Company, 700 Bay Road, Redwood City, Califor-
 nia 94063 (US). **GANGWAR, Sanjeev**; c/o Bristol-Myers
 Squibb Company, 700 Bay Road, Redwood City, Califor-
 nia 94063 (US). **SUFI, Bilal**; c/o Bristol-Myers Squibb
 Company, 700 Bay Road, Redwood City, California 94063
 (US).

(74) Agents: **CHAO, Yuan** et al.; Bristol-Myers Squibb Com-
 pany, P.O. Box 4000, Princeton, New Jersey 08543-4000
 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
 ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
 patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR



(57) Abstract: Enediyne compounds having a structure according to formula (I), where R^0 , R^2 , R^3 , R^4 , R^5 , R^6 , and R^7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.